Emma Blake's Archive

Emma is a junior at Brown University. She is studying Health and Human Biology and planning on attending medical school after completing her undergraduate education. In her spare time, Emma enjoys running, biking, reading, and spending time with her family and friends. Emma joined The Myeloma Beacon team in August 2013.

Emma Blake has written 8 article(s) .

[ by and | Mar 20, 2014 1:55 pm | 3 Comments ]
Researchers Express Concern About Scar Tissue And Extramedullary Disease In Multiple Myeloma Patients

A team of Israeli researchers has expressed concern that surgical scars may be a particularly favorable environment for the development of difficult-to-treat extra­med­ul­lary disease in multiple myeloma patients.

Extramedullary disease occurs when myeloma cells form tumors outside of a patient’s bones.

The Israeli researchers also suggest that novel anti-myeloma therapies –such as thalidomide (Thalomid), Revlimid (lenalidomide), or Velcade (bortezomib) – and perhaps stem cell transplantation may foster the de­vel­op­ment of extra­med­ul­lary disease in scar …

Tags: , , ,
Read the full story »
[ by and | Feb 19, 2014 5:11 pm | 7 Comments ]
Multiple Myeloma Molecular Subtypes Are Already Present In MGUS And Smoldering Myeloma Patients

Results of a recent observational study show that all known molecular subtypes of multiple myeloma are already present at the early, smol­der­ing myeloma and monoclonal gammopathy of undetermined significance stages of the disease.

According to the investigators, these findings indicate that the various molecular subtypes of myeloma, which have different genetic char­ac­ter­istics, are es­tab­lished early in the course of the disease.

The researchers defined the different molecular subtypes of myeloma they investigated based on a method called gene ex­pres­sion profiling. …

Tags: , , , , , , ,
Read the full story »
[ by and | Dec 30, 2013 11:48 pm | 2 Comments ]
Further Evidence Of A Positive Link Between Weight At Diagnosis And Survival In Multiple Myeloma Patients

In a recent study conducted in Korea, investigators found that myeloma patients who had higher weights at diagnosis had the longest survival.

Patients who were underweight at diagnosis, on the other hand, had the lowest survival.

The results of the Korean study are similar to those reported by a recent study that examined weight at diagnosis and its impact on survival in U.S. veterans diagnosed with myeloma (see related Beacon news).

In the Korean study, investigators retrospectively analyzed data for …

Tags: , , , , , , ,
Read the full story »
[ by | Dec 2, 2013 5:12 pm | 2 Comments ]
ASH 2013 Preview: Revlimid Maintenance Therapy For Multiple Myeloma

Results of several studies investigating Revlimid main­te­nance ther­a­py for mul­ti­ple myeloma will be presented at this year’s American Society of Hema­tol­ogy (ASH) annual meeting, which starts later this week.

Today’s article previews the results of the key Revlimid main­te­nance studies that will be presented at the meeting, drawing on findings pub­lished in the meeting abstracts.  Some of the study results, it should be noted, will be updated during the presentations at ASH this week and early next week.

The results …

Tags: , , , , , , ,
Read the full story »
[ by | Nov 6, 2013 5:03 pm | 7 Comments ]
Chromosomal Abnormalities And Tumor Load Linked To More Rapid Progression In Smoldering Myeloma Patients

German researchers recently reported that certain chromo­som­al ab­nor­mal­i­ties in patients' myeloma cells are associated with more rapid pro­gression from smol­der­ing myeloma to active, or symptomatic, mul­ti­ple myeloma.

Specifically, patients in the study who had the chromo­som­al ab­nor­mal­i­ties del(17p), t(4;14), and 1q gain, as well as patients with more chromo­somes than normal (hy­per­dip­loi­dy), experienced shorter times until pro­gression to sympto­matic myeloma.

Previous studies have shown that hy­per­dip­loi­dy positively affects out­comes for patients with symptomatic myeloma. In this study, however, the investigators …

Tags: , , ,
Read the full story »
[ by | Oct 23, 2013 6:16 pm | Comments Off ]
Milatuzumab Alone Shows Limited Efficacy In Relapsed and Refractory Myeloma Patients

Results of a small Phase 1 study indicate that the investigational drug mila­tu­zu­mab on its own has limited efficacy in patients with advanced relapsed and re­fractory multiple myeloma.

The best response the investigators observed in their study was stable disease, which 20 percent of the patients achieved. One patient con­tin­ued to have stable disease without progression for 17 months.

According to the investigators, these results are in line with those for sev­er­al other agents in the same class of drugs, …

Tags: , ,
Read the full story »
[ by | Oct 16, 2013 3:13 pm | 7 Comments ]
Addition Of Zolinza Slightly Improves Velcade Treatment For Relapsed Myeloma Patients

Results of a recent international Phase 3 study demonstrate that the addi­tion of Zolinza to Velcade increases response rates and slightly im­proves progression-free survival in relapsed and refractory myeloma patients compared to treatment with Velcade alone.

Specifically, 56 percent of patients responded to treatment with Zolinza (vorin­o­stat) plus Velcade (bortezomib) compared to 41 percent of patients treated with Velcade plus placebo.

However, despite improvements in responses, the difference in pro­gres­sion-free survival between the two treatment groups …

Tags: , , , , ,
Read the full story »